Story perspectives

J&J Ordered to Pay $40M for Talc Cancer Claims

12/13/2025

Summary

Kent and Schultz Win

Los Angeles jury awarded $40 million to Monica Kent and Deborah Schultz for ovarian cancer caused by Johnson & Johnson's talcum powder.
Kent received $18 million, and Schultz received $22 million.
The jury found Johnson & Johnson long knew talc dangers but did not warn consumers.
J&J plans to appeal, and faces more than 67,000 talc-related lawsuits.
The company discontinued talc-based baby powder in the United States in 2020.

Summary

Johnson & Johnson Empowers

Johnson & Johnson (the company) launched the "3rd Opinion" campaign in Singapore to improve shared decision-making for lung cancer patients.
The campaign was highlighted at ESMO Asia 2025 Symposium.
A survey found 90% of Japanese lung cancer patients want active involvement.
Johnson & Johnson’s activations include educational materials and digital engagement across Asia Pacific to align treatment with patient preferences and improve satisfaction and outcomes.

History

Historical Context

Johnson & Johnson's talc-based baby powder, introduced in 1894, faced scrutiny after the International Agency for Research on Cancer classified talc as a possible carcinogen in 2006. By 2020, amid over 67,000 lawsuits and significant jury awards, the company discontinued the product in the U.S. This legal battle highlights increasing consumer protection and accountability in product safety, potentially leading to stricter regulations.

1 of 3

Kent and Schultz Win

Los Angeles jury awarded $40 million to Monica Kent and Deborah Schultz for ovarian cancer caused by Johnson & Johnson's talcum powder.
Kent received $18 million, and Schultz received $22 million.
The jury found Johnson & Johnson long knew talc dangers but did not warn consumers.
J&J plans to appeal, and faces more than 67,000 talc-related lawsuits.
The company discontinued talc-based baby powder in the United States in 2020.

1 / 3